Tags

Type your tag names separated by a space and hit enter

Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer.
Int J Drug Policy. 2010 Nov; 21(6):511-3.IJ

Abstract

BACKGROUND

Debates about cannabis policy often mention respiratory symptoms as a negative consequence of use. The cannabis vaporizer, a machine that heats the plant to release cannabinoids in a mist without smoke and other respiratory irritants, appears to have the potential to minimize respiratory complaints.

METHODS

Twenty frequent cannabis users (uninterested in treatment) reporting at least two respiratory symptoms completed subjective ratings of respiratory symptoms and spirometry measures prior to and following 1 month's use of a cannabis vaporizer in a pre/post-design. Outcome measures included self-reported severity of nine respiratory symptoms as well as spirometry measures, including the maximum amount of air exhaled in 1s (forced expiratory volume; FEV1) and maximum total lung volume (forced vital capacity; FVC).

RESULTS

The 12 participants who did not develop a respiratory illness during the trial significantly improved respiratory symptoms (t(11)=6.22, p=0.000065, d=3.75) and FVC, t(11)=2.90, p=0.007, d=1.75. FEV1 improved but not significantly t(11)=1.77, p=0.053, d=1.07.

CONCLUSIONS

These preliminary data reveal meaningful improvements in respiratory function, suggesting that a randomized clinical trial of the cannabis vaporizer is warranted. The vaporizer has potential for the administration of medical cannabis and as a harm reduction technique.

Authors+Show Affiliations

Department of Psychology, University at Albany, SUNY, Albany, NY 12222, USA.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20451365

Citation

Van Dam, Nicholas T., and Mitch Earleywine. "Pulmonary Function in Cannabis Users: Support for a Clinical Trial of the Vaporizer." The International Journal On Drug Policy, vol. 21, no. 6, 2010, pp. 511-3.
Van Dam NT, Earleywine M. Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer. Int J Drug Policy. 2010;21(6):511-3.
Van Dam, N. T., & Earleywine, M. (2010). Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer. The International Journal On Drug Policy, 21(6), 511-3. https://doi.org/10.1016/j.drugpo.2010.04.001
Van Dam NT, Earleywine M. Pulmonary Function in Cannabis Users: Support for a Clinical Trial of the Vaporizer. Int J Drug Policy. 2010;21(6):511-3. PubMed PMID: 20451365.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer. AU - Van Dam,Nicholas T, AU - Earleywine,Mitch, Y1 - 2010/05/06/ PY - 2010/02/24/received PY - 2010/03/25/revised PY - 2010/04/04/accepted PY - 2010/5/11/entrez PY - 2010/5/11/pubmed PY - 2011/3/8/medline SP - 511 EP - 3 JF - The International journal on drug policy JO - Int J Drug Policy VL - 21 IS - 6 N2 - BACKGROUND: Debates about cannabis policy often mention respiratory symptoms as a negative consequence of use. The cannabis vaporizer, a machine that heats the plant to release cannabinoids in a mist without smoke and other respiratory irritants, appears to have the potential to minimize respiratory complaints. METHODS: Twenty frequent cannabis users (uninterested in treatment) reporting at least two respiratory symptoms completed subjective ratings of respiratory symptoms and spirometry measures prior to and following 1 month's use of a cannabis vaporizer in a pre/post-design. Outcome measures included self-reported severity of nine respiratory symptoms as well as spirometry measures, including the maximum amount of air exhaled in 1s (forced expiratory volume; FEV1) and maximum total lung volume (forced vital capacity; FVC). RESULTS: The 12 participants who did not develop a respiratory illness during the trial significantly improved respiratory symptoms (t(11)=6.22, p=0.000065, d=3.75) and FVC, t(11)=2.90, p=0.007, d=1.75. FEV1 improved but not significantly t(11)=1.77, p=0.053, d=1.07. CONCLUSIONS: These preliminary data reveal meaningful improvements in respiratory function, suggesting that a randomized clinical trial of the cannabis vaporizer is warranted. The vaporizer has potential for the administration of medical cannabis and as a harm reduction technique. SN - 1873-4758 UR - https://www.unboundmedicine.com/medline/citation/20451365/Pulmonary_function_in_cannabis_users:_Support_for_a_clinical_trial_of_the_vaporizer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0955-3959(10)00069-1 DB - PRIME DP - Unbound Medicine ER -